Strong underlying demand for plasma-derivative drugs and COVID-19 tests propelled the top line in Q3. Moreover, the recovery in plasma-collection bolstered the profitability. Grifols has initiated >25 plasma-based trials for the treatment of COVID-19 and convalescent plasma has already received a go-ahead from the FDA, though NIH’s suspicion over its efficacy has limited its usage. In Q4, the surge in demand for COVID-19 tests should fuel growth. Moreover, expansion in the CNS space – through th ....
06 Nov 2020
Growth to (accelerate?) with COVID-19 test in the kitty
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Growth to (accelerate?) with COVID-19 test in the kitty
Strong underlying demand for plasma-derivative drugs and COVID-19 tests propelled the top line in Q3. Moreover, the recovery in plasma-collection bolstered the profitability. Grifols has initiated >25 plasma-based trials for the treatment of COVID-19 and convalescent plasma has already received a go-ahead from the FDA, though NIH’s suspicion over its efficacy has limited its usage. In Q4, the surge in demand for COVID-19 tests should fuel growth. Moreover, expansion in the CNS space – through th ....